key: cord-0734063-9bs6ilog
authors: Long, M. D.; Weaver, K. N.; Zhang, X.; Chun, K.; Kappelman, M. D.; Watkins, R.; Adler, J.; Dubinsky, M. C.; Kastl, A.; Bousvaros, A.; Strople, J. A.; Cross, R. K.; Higgins, P.D.R.; Ungaro, R. C.; Bewtra, M.; Bellaguarda, E.; Farraye, F. A.; Boccieri, M. E.; Firestine, A.; Fernando, M.; Bastidas, M.; Zikry, M.; Dai, X.
title: Strong Response to SARS-CoV-2 Vaccine Additional Doses among Patients with Inflammatory Bowel Diseases
date: 2022-02-09
journal: Clin Gastroenterol Hepatol
DOI: 10.1016/j.cgh.2022.01.056
sha: 8fada9b6289ff4ec214a3eb59bed693039cd1a28
doc_id: 734063
cord_uid: 9bs6ilog

nan

The SARS-CoV-2 pandemic has disrupted health care and has resulted in high mortality rates. 1 Vaccination is an international priority to mitigate the risks of SARS-CoV-2. The initial trials for development of SARS-CoV-2 vaccines excluded individuals with immunocompromising conditions. 2 As individuals on immunosuppression, including those with inflammatory bowel diseases (IBD), may not mount as robust an antibody titer to vaccination, 3, 4 the Food and Drug Administration (FDA) has recommended an additional dose after the initial series. 5 To date, little is known about the effectiveness and safety of additional vaccine doses in patients with IBD. We sought to quantify the humoral immune response to an additional vaccine in this population.

Partnership to Report Effectiveness of Vaccination in populations Excluded from iNitial Trials of COVID (PREVENT-COVID) is a prospective, observational, cohort of patients with IBD who have received any SARS-CoV-2 vaccine granted emergency use authorization (EUA) with initial enrollment in March of 2021. Methods for PREVENT-COVID have previously been described. 6 Here we analyzed data on participants who completed baseline and follow-up surveys, had samples obtained 8 weeks following initial vaccination series, and samples 3-8 weeks following an additional vaccine. We excluded those who self-reported prior COVID-19 infection and/or who had positive nucleocapsid assay sat baseline. Side effects to vaccine were self-reported as none, mild, moderate, severe or very severe. We performed quantitative measurement of anti-receptor binding domain (RBD) IgG antibodies specific to SARS-CoV-2 using the LabCorp Cov2Quant IgG™ assay. 6 Results of 1.0 g/mL or greater suggest "detectable" serologic response to vaccination and/or prior infection with SARS-CoV-2.

We used descriptive statistics to characterize the population and anti-spike antibody levels before and after additional vaccine and determined the rate of seroconversion among those who were initially undetectable. Variables included age, sex, diseasesubtype, vaccine type (BNT162b2 vs mRNA-1273), time since vaccination, and use of IBD medications. We report median antibody level (interquartile J o u r n a l P r e -p r o o f range, IQR) after initial series, after additional vaccination, and the delta (standard deviation) for each vaccine type. We used Wilcoxon rank sum to compare median change in antibody level with additional SARS-CoV-2 vaccination by detectable response to initial vaccine series. We utilized a linear regression model where quartiles of antibody levels were treated as a continuous variable (1,2,3,4) to determine factors independently associated with level of antibody response. All analyses were performed using Figure 1 , with higher antibody titer after mRNA-1273. Additional vaccination was generally well tolerated in this population, with 44% having no side effects, 24% mild, 25% moderate and 6%

severe.

These findings demonstrate substantial immunogenicity to additional doses of SARS-CoV-2 vaccine, even amongst IBD patients with undetectable antibody following the initial series. The highest increase in antibody titer was seen with an additional dose of mRNA-1273. Combination anti-TNF therapy was associated with a significant reduction in antibody titer. Reassuringly, adverse event rates were low among patients receiving an additional vaccination of any type. A recently published series of cancer patients showed 93.7% mounting a detectable humoral vaccine response 2-9 weeks after the initial vaccine series. A third vaccine given to 30 patients with persistently low antibody titers resulted in 88.5% seroconversion rate. 7 In 17 patients with rheumatoid arthritis (RA) who did not mount an initial response to SARS-CoV-2 vaccine, 15 patients reached moderate to maximal post-vaccine titers after additional vaccine. However, in this RA population 16/17 patients held their disease modifying agents prior to the additional vaccine. 8 In our IBD population, 95.7% of those with an initial undetectable response (n=47) developed a detectable humoral response to an additional vaccine, comparable to results in other immunosuppressed populations. Importantly, recommendations in IBD do not include holding immunosuppressive therapies prior to vaccination. 9 There are a number of strengths to this large prospective study of humoral vaccine response to additional SARS-CoV-2 vaccine in patients with IBD. The cohort is geographically diverse, contributing to generalizability across the US population. The large sample size allows for precise estimates of humoral vaccine response to an additional vaccine dose in patients with IBD. Study limitations include a convenience sample that may not represent the broader US population and the reliance of self-report for details regarding immunization. The relatively low rate of initial undetectable antibody titer makes subgroup analysis difficult to determine independent medication effects of seroconversion with 

Epidemiology and pathobiology of SARS-CoV-2 (COVID-19) in comparison with SARS, MERS: An updated overview of current knowledge and future perspectives

Comparative Effectiveness of Moderna

COVID-19 mRNA Vaccine Immunogenicity in Immunosuppressed Individuals. The Journal of infectious diseases

Predictors of poor seroconversion and adverse events to SARS-CoV-2 mRNA BNT162b2 vaccine in cancer patients on active treatment

Humoral Immune Response to Messenger RNA COVID-19 Vaccines Among Patients With Inflammatory Bowel Disease

Efficacy of SARS-CoV-2 vaccine in thoracic cancer patients: a prospective study supporting a third dose in patients with minimal serologic response after two vaccine doses

Efficacy and tolerability of a third dose of an mRNA anti-SARS-CoV-2 vaccine in patients with rheumatoid arthritis with absent or minimal serological response to two previous doses. The Lancet. Rheumatology

SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting